UPDATE: Trillium Therapeutics (TRIL) Halted on LUDP After Plunging 30% on Safety Concerns
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - November 3, 2016 9:55 AM EDT)
Trillium Therapeutics (NASDAQ: TRIL) slammed following update and now halted on LUDP. Last down 30%.
UPDATE: Downside comes from safety concerns noted in ASH abstracts: "The 0.3 ng/kg dose was associated with reversible, dose-limiting toxicity (DLT) of 2 of 2 points: one pt with G3 elevated ALT/AST and G4 platelet count, and a second pt with G4 platelet count who was transfused."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neovasc (NVCN) Climbs to Session High, Shares Up 125%
- Financial Select Sector SPDR ETF (XLF) calls active on 4 calls to 1 put
- Options expected to have Increasing volume: BOBE KMI COST TOL HRB LULU
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!